Autosomal Dominant Polycystic Kidney Disease
Intracranial Aneurysms in ADPKD: A Call for Streamlined, Evidence-Based Screening Protocols
The screening protocol for intracranial aneurysm in patients with autosomal dominant polycystic kidney disease should be based on the presence and size of the aneurysm, family history, and age, and should use non-contrast magnetic resonance angiography.
How Did COVID-19 Affect ADPKD Care?
Patients with autosomal-dominant polycystic kidney disease were assessed to determine whether the COVID-19 pandemic disrupted disease management and care.
In ADPKD, A Better Way to Characterize Patients’ Rapid Decline
Researchers recently set out to learn which factors predict rapid decline in patients with autosomal dominant polycystic kidney disease (ADPKD), and how this information could help clinicians manage (and perhaps slow) its course toward end-stage kidney disease.
video
In Patients With ADPKD, Why Pursue Counseling Before Testing?
Therapy may not be indicated in many cases, explains David Charytan, MD, MSc, of NYU Langone. And for those who are asymptomatic, "there can be significant psychological implications." (2:19)
How Does ADPKD Affect Quality of Life?
A team of 10 U.S.-based investigators delved deeper into how autosomal dominant polycystic kidney disease affects patients’ health-related quality of life and pain levels. Here’s what they found.
VA Study Establishes Largest Cohort to Date for Predictive Modeling in ADPKD
With data from the U.S. Veterans Health Administration, these investigators found higher rates of comorbidities, disproportionate representation of Black/African American patients, and differences in eGFR trajectories among various patient subgroups with autosomal dominant polycystic kidney disease.
Imaging Patterns in ADPKD and the Problem With Kidney Stones
Patients with autosomal dominant polycystic kidney disease have more kidney stones than the general population, with a consequent decline in estimated glomerular filtration rate, more abdominal imaging, and possible increased financial, physical, and personal burdens.
In Autosomal Polycystic Kidney Disease, Is Urinary DKK3 a Predictive Biomarker?
Urinary DKK3 may be a biomarker that can help predict loss of renal function in patients with autosomal dominant polycystic kidney disease.
Using Statins in Patients with ADPKD
The data is inconsistent, explains David Charytan, MD, MSc, of NYU Grossman School of Medicine. While statins show promise in animal models, clinical trials in humans are a different story. (1:32)
Semi-Automatic Volumetric Segmentation and Ellipsoid Methods for Kidney Volume Assessment
Kidney volume assessment using MRI is important for patients with ADPKD. The ellipsoid and semi-automatic volumetric segmentation methods were compared for single and total kidney volume computation. The ellipsoid method is more operator-dependent than the semi-automatic volumetric segmentation method.
In Patients with ADPKD, Vascular Complications are Common but Treatable
Patients with autosomal dominant polycystic kidney disease are at a greatly increased risk for vascular complications, including intracranial aneurysms (ICA). Targeted screening can help identify patients with ICA at risk for rupture and facilitate intervention.
In ADPKD, WBC Count Does Not Appear to Affect Transplant Outcomes
Researchers from Belgium found that overall survival and kidney transplant survival was better in patients with ADPKD vs non-ADPKD, but data were not conclusive on the association between WBC and outcomes.
Does Gene Therapy Have a Role in ADPKD?
Genes implicated in polycystic kidney disease are more complex than other diseases, which complicates the development of therapies, explains David Charytan, MD, MSc, of the NYU Grossman School of Medicine. "It's probably the wave of the future," he says. (1:24)
In ADPKD, Using AI to Measure Total Kidney Volume
Mayo Clinic researchers recently studied an algorithm based on artificial intelligence (AI) for measuring magnetic resonance-derived total kidney volume in autosomal dominant polycystic kidney disease against manually edited segmentations.
ADPKD Patient Perspectives: What Toll Does Uncertainty Take?
Patients with autosomal dominant polycystic kidney disease have their own regrets about how they’ve managed their disease, but they also blame healthcare providers for not opening their eyes to ways of improving their physical and psychological well-being, say the results of this report.
In Autosomal Dominant Polycystic Kidney Disease, What Indicates Progression?
A Japanese study examined differences in total kidney volume and total liver volume in patients with autosomal dominant polycystic kidney disease receiving either peritoneal dialysis or hemodialysis. Some findings were unexpected.
Screening for Cerebral Aneurysm in ADPKD
David Charytan, MD, MSc, of NYU Grossman School of Medicine, explains when it's appropriate to screen for cerebral aneuryism in ADPKD patients. (1:10)
Q&A: Rupesh Raina, MBBS, on the Cardiovascular Implications of Hypertensive ADPKD
Dr. Raina discusses his recent review and meta-analysis on cardiovascular pathologies in patients with ADPKD in an interview with MedPage Today.
In Autosomal Dominant Polycystic Kidney Disease, Using Exome Sequencing to Aid Diagnosis
This study demonstrated substantial genetic and phenotype variability in ADPKD among patients, which researchers propose could be used as a tool for ADPKD diagnosis.
Kidney and Liver Volumetry: Deep-Learning Model Enables Accurate Segmentation
A deep-learning model for fully automated joint kidney and liver segmentation was recently shown to be a robust and accurate tool for rapid estimation of kidney and liver volume. But is it feasible to implement it into routine clinical care?
Q&A: Dinushika Mohottige, MD and Lisa McElroy, MD on ADPKD Health Inequities
Drs. Mohottige and McElroy comment about factors that may contribute to prevalent racial and ethnic disparities in ADPKD outcomes, as well as possible ways to achieve equity in ADPKD care.
In ADPKD, What Are the Risk Factors for Intracranial Aneurysm?
According to a new study from Tokyo, decline in kidney function and increased kidney volume may be risk factors for intracranial aneurysm in patients with autosomal dominant polycystic kidney disease.
In Autosomal Dominant Polycystic Kidney Disease, What are the Risk Factors for Disease Progression?
Korean investigators sought to identify risk factors associated with ADPKD progression. A standard therapy for slowing the advance to end stage renal disease is lacking.
National Registry Provides Insights into Autosomal Dominant Polycystic Kidney Disease
The Polycystic Kidney Disease Foundation established the first national ADPKD Registry to facilitate therapeutic research on ADPKD, which has been limited by lack of an organized patient database.